Medicine and HealthNature Medicine

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

Discover the groundbreaking results of the DESTINY-Breast03 trial, where trastuzumab deruxtecan (T-DXd) demonstrated remarkable efficacy over trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer treatment. With a follow-up of 41 months, T-DXd achieved a median overall survival of 52.6 months, changing the landscape of breast cancer therapy. This impactful research was conducted by an esteemed group of authors.... show more

Related Publications

Explore these studies to deepen your understanding

Adjacent work that informs or extends this paper's methodology and findings.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

N. Harbeck, E. Ciruelos, et al.

Medicine and Health

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

D. H. Ryan, I. Lingvay, et al.

Political Science

'Climate change concerns human survival...and justice in our international community': A corpus-based positive discourse analysis (PDA) of the largest developing nation's global involve/engagement discourses (re)told in interpreting

C. Gu

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 22+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny